SCHEDULE: Adage Capital Discloses 5.35% Stake in Wave Life Sciences
Beneficial Ownership Report
Adage Capital Management and its principals report a 5.35% beneficial ownership stake in Wave Life Sciences Ltd. as of December 31, 2025.
Summary
- Adage Capital Management, L.P., along with Robert Atchinson and Phillip Gross, collectively reported beneficial ownership of 9,786,061 Ordinary Shares of Wave Life Sciences Ltd.
- This ownership represents 5.35% of the company's Ordinary Shares outstanding.
- The calculation of the percentage is based on an aggregate of 182,971,259 Ordinary Shares outstanding, which includes 15,789,475 shares offered via a prospectus filed on December 11, 2025, and 167,181,784 shares outstanding as of November 7, 2025.
- The reporting persons hold shared voting and shared dispositive power over all 9,786,061 shares.
- This filing is an Amendment No. 5 to a previous Schedule 13G statement.
Sentiment
Score: 6
Explanation: StockSavvy.ai views this as a neutral-to-slightly-positive filing. It's a routine disclosure of a significant, ongoing institutional stake, which can be interpreted as a vote of confidence, but it provides no new operational or financial insights into the company itself.
Positives
- The continued significant stake by an institutional investor like Adage Capital Management may signal confidence in Wave Life Sciences Ltd.'s long-term prospects.
Negatives
- This filing is a routine disclosure of beneficial ownership and does not contain information that would typically be categorized as negative regarding the issuer's performance or outlook.
Risks
- This Schedule 13G filing does not contain specific risk factors related to Wave Life Sciences Ltd.'s operations or financial health.
Future Outlook
This Schedule 13G filing is a disclosure of beneficial ownership and does not contain forward-looking statements or guidance from Wave Life Sciences Ltd. or the reporting persons regarding the company's future outlook.
Management Comments
- Robert Atchinson, as Managing Member of Adage Capital Partners LLC (General Partner of Adage Capital Management, L.P.), certified that the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of the issuer.
Industry Context
StockSavvy.ai notes that institutional ownership reports like this Schedule 13G provide transparency into significant investor positions. While not directly indicative of industry trends, the continued presence of major funds like Adage Capital in the biotechnology sector, where Wave Life Sciences operates, suggests ongoing investor interest in innovative therapeutic companies.
Stakeholder Impact
- Shareholders: Provides transparency regarding a significant institutional holder's stake, which can influence market perception and liquidity.
- Investment Professionals: Offers insight into the holdings of a prominent investment manager, potentially informing their own investment decisions.
Key Dates
| Date | Description |
|---|---|
| 2025-09-30 | End of quarterly period for which Wave Life Sciences Ltd. filed its Form 10-Q. |
| 2025-11-07 | Date as of which 167,181,784 Ordinary Shares were outstanding, as reported in the company's Form 10-Q. |
| 2025-11-10 | Date Wave Life Sciences Ltd. filed its Quarterly Report on Form 10-Q for the period ended September 30, 2025. |
| 2025-12-11 | Date Wave Life Sciences Ltd. filed a Prospectus pursuant to Rule 424(b)(4) for an offering of 15,789,475 Ordinary Shares. |
| 2025-12-31 | Date of event which requires filing of this statement (reporting period end date). |
| 2026-02-12 | Filing date of this Schedule 13G Amendment No. 5. |
Keywords
Wave Life Sciences, Adage Capital Management, Beneficial Ownership, Schedule 13G, Institutional Investor, Ordinary Shares, Biotechnology, SEC Filing
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.